News

Silexion Reports Breakthrough Preclinical Results, Showing Up to 97% Inhibition in KRAS-Driven Cancer Cells

Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data for its investigational drug, SIL204, designed to target KRAS mutations in various cancers. The data revealed inhibition rates of 97% in pancreatic cancer cells and 90% in colorectal cancer cells, marking a significant step forward in developing therapies for some of the most aggressive forms of cancer.

The results represent the company’s first evidence of safety and efficacy against the KRAS Q61H mutation, a clinically important but previously untested target in human cancer cells. SIL204 continues to demonstrate its promise as a pan-KRAS therapeutic candidate, addressing multiple KRAS mutations across cancer types.

Building on Prior Studies

The new data builds upon earlier studies that tested SIL204’s activity across various cancer models. Using CellTiter-Glo (CTG) analysis, researchers performed a direct comparison of SIL204’s effectiveness against multiple KRAS mutations. The study also showed dose-dependent inhibition of up to 94% in pancreatic cells with KRAS G12D mutations, and notably, 87% inhibition in cells with the KRAS Q61H mutation, a mutation previously unexplored by Silexion.

These results follow earlier findings that demonstrated SIL204’s effectiveness in lung cancer cell lines, providing further validation of Silexion’s lipid-conjugated delivery platform for RNAi-based cancer therapeutics.

Executive Insight

Silexion Chairman and CEO Ilan Hadar commented on the development:

“These findings have provided engaging evidence of SIL204’s potential activity against various KRAS mutations across multiple cancer types. The capability to achieve such a level of inhibition in colorectal and pancreatic cancer models with multiple KRAS mutations exponentially strengthens SIL204’s ability as a pan-KRAS therapeutic candidate.”

Become a valued research partner with ushttps://www.towardshealthcare.com/schedule-meeting

He added:

“With these positive results in all three crucial KRAS-targeted cancer types lung, pancreatic, and colorectal—we are elevating our confidence in SIL204’s potency to address major unmet needs for severe cancer patients.”

Path Forward

Silexion is now preparing to advance SIL204 into Phase 2/3 clinical trials in Q2 2026, focusing on KRAS-driven solid tumors. The trials will incorporate both systemic and intratumoral delivery approaches, part of the company’s dual-path administration strategy aimed at maximizing therapeutic impact.

The strong preclinical evidence across multiple KRAS mutations positions SIL204 as a potentially transformative treatment option in the oncology space, particularly for patients battling treatment-resistant forms of cancer.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com

sanskruti sathe

Recent Posts

Azenta and Frenova Partner to Accelerate Genomic Research in Nephrology Through MyReason® Program

Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More

4 hours ago

Zenara Pharma Receives FDA Approval for First Generic Sertraline Hydrochloride Capsules with 180-Day Marketing Exclusivity

Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More

4 hours ago

Genvira, Labskin, and NRC Launch Joint Canada-UK Initiative to Advance Melanoma Immunotherapies

Canada and the UK have joined forces in a groundbreaking project aimed at developing next-generation immunotherapies for malignant melanoma, a… Read More

5 hours ago

Liquid Filtration for Pharmaceutical Market Companies Driving Innovation & Growth

The liquid filtration for pharmaceutical market is rapidly evolving and is poised to generate hundreds of millions in revenue between… Read More

1 day ago

Ophthalmology Devices Market Companies Driving Growth to 2034

The global ophthalmology devices market is valued at USD 7.51 billion in 2024 and is projected to grow to USD… Read More

1 day ago

Xenetic Biosciences and Periness Enter Clinical Study Agreement to Advance DNase 1 Platform for Large B-Cell Lymphoma Treatment

Xenetic Biosciences, Inc., a biopharmaceutical company pioneering in immuno-oncology, has entered into a clinical study agreement with Periness Ltd. to… Read More

1 day ago